SRDX

SRDX

USD

Surmodics Inc. Common Stock

$27.500-0.550 (-1.961%)

リアルタイム価格

Healthcare
医療機器
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$28.050

高値

$28.120

安値

$27.400

出来高

0.11M

企業ファンダメンタルズ

時価総額

393.2M

業種

医療機器

United States

取引統計

平均出来高

0.18M

取引所

NMS

通貨

USD

52週レンジ

安値 $26現在値 $27.500高値 $40.39

関連ニュース

BusinessWire

Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations

Analysis of the all-comers PROWL Registry demonstrated high procedural success and safety in a cohort reflecting the real-world complexity of patients with symptomatic limb ischemia, over 40% of whom had symptoms

もっと見る
Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations
BusinessWire

Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3

PROWL Registry evaluates the Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. Updated safety and performance data from 160 patients with

もっと見る
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
BusinessWire

Surmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce™ Thrombectomy Platform

Analysis of 160 patients with acute, subacute, or chronic symptoms of thrombotic limb ischemia receiving thromboemboli removal treatment with the Pounce™ Thrombectomy Platform demonstrated high procedural success

もっと見る
Surmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce™ Thrombectomy Platform
BusinessWire

Surmodics Announces PROWL Registry Sex-Specific Data to be Presented at TCT Conference on October 28

PROWL Registry evaluates the Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. Results of a sex-specific analysis of 160 patients with

もっと見る
Surmodics Announces PROWL Registry Sex-Specific Data to be Presented at TCT Conference on October 28